Progression From Newly Acquired Impaired Fasting Glucose to Type 2 Diabetes
Response to Nichols et al.
- Sean F. Dinneen, MD1 and
- Robert A. Rizza, MD2
- 1Department of Medicine, National University of Ireland, Galway, Ireland
- 2Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota
- Address correspondence to Sean F. Dinneen, MD, Department of Medicine, National University of Ireland, Newcastle Road, Galway, Ireland. E-mail: sean.dinneen{at}nuigalway.ie
We read with interest the report by Nichols et al. (1) on progression from impaired fasting glucose (IFG) to type 2 diabetes among 5,452 members of the Kaiser Permanente Northwest HMO. Their analysis includes a very thorough assessment of the impact of the new American Diabetes Association (ADA) criteria for IFG on future risk of diabetes. They conclude that the older criteria for IFG (110–125 mg/dl) are more predictive of future diabetes. The authors suggest that their study is the first to report diabetes incidence in routine clinical practice using the …
